Parallel trade of pharmaceutical products: the ECJ finally speaks— Comment on GlaxoSmithKline
Petrucci, Carlo 2010, 'Parallel trade of pharmaceutical products: the ECJ finally speaks— Comment on GlaxoSmithKline' , European Law Review (2) , pp. 275-286.
- Published Version
Restricted to Repository staff only
Download (322kB) | Request a copy
This article reviews the ECJ’s judgment in GlaxoSmithKline that overturned some important findings of the CFI’s decision. It criticises the longstanding problematic distinction between anti-competitive object and effect and, in particular, whether distribution agreements that limit parallel trade fit into the category of agreement having an anti-competitive object. Given that the ECJ’s decision reasserted a multi- goal approach to EU competition law, it is argued that the judgment leaves some issues unresolved. Similarly, the issues of the effects of price regulation and research and development (R&D) funding have not been dealt with adequately.
|Themes:||Subjects outside of the University Themes|
|Schools:||Schools > Salford Business School > Business and Management Research Centre|
|Journal or Publication Title:||European Law Review|
|Publisher:||Sweet & Maxwell|
|Depositing User:||Mr Carlo Petrucci|
|Date Deposited:||15 Nov 2011 10:32|
|Last Modified:||29 Oct 2015 00:48|
Actions (login required)
|Edit record (repository staff only)|